Sara Tolaney

Sara Tolaney leads clinical breast cancer research at Dana-Farber and has made major contributions to the development and clinical evaluation of antibody-drug conjugates in triple-negative breast cancer. She was a key investigator in the ASCENT trial establishing sacituzumab govitecan in previously treated metastatic TNBC and has contributed to clinical development in early-stage disease. She has been involved in multiple FDA-approval enabling studies in breast cancer and is among the most influential breast oncologists of her generation. She leads one of the world's largest breast cancer clinical trial programs.